Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM (QCOM), as well as two micro-cap stocks CSP Inc. (CSPI) and AMCON ...

and new products have been driving Merck’s sales. With continued label expansion into new indications, particularly earlier-stage launches, Keytruda is expected to see continued growth. Animal ...

Merck Research Laboratories. “We are grateful to the dedicated community of patients who participated in these studies and are pleased to offer the option of receiving WINREVAIR through the Phase 3 ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study Merck (NYSE: MRK), known as MSD ...